Almirall strengthens its German business with two new products: Sativex® and Actikerall®

Barcelona, 5 th July 2011.- Almirall, S.A. (ALM:MC) announces the launch, in Germany, of Sativex ® for the treatment of spasticity in multiple sclerosis (MS) and the approval of Actikerall ® for the treatment of hyperkeratotic actinic keratosis (grade I/II) in adult patients which will be launched on July 15 th . This represents a step forward for Almirall to reinforce our presence in European markets and is also an important milestone in our offering society innovative medicines to fulfil unmet medical needs.

The release as fetched from its publisher. almirall.com ↗